HK1054548B - 法呢基蛋白轉移酶抑制劑三環抗腫瘤化合物 - Google Patents

法呢基蛋白轉移酶抑制劑三環抗腫瘤化合物

Info

Publication number
HK1054548B
HK1054548B HK03105016.6A HK03105016A HK1054548B HK 1054548 B HK1054548 B HK 1054548B HK 03105016 A HK03105016 A HK 03105016A HK 1054548 B HK1054548 B HK 1054548B
Authority
HK
Hong Kong
Prior art keywords
protein transferase
transferase inhibitors
farnesyl protein
antitumor compounds
tricyclic
Prior art date
Application number
HK03105016.6A
Other languages
English (en)
Other versions
HK1054548A1 (en
Inventor
F George Njoroge
Bancha Vibulbhan
Alan B Cooper
Timothy Guzi
Dinanath F Rane
Keith P Minor
Ronald J Doll
Viyyoor Moopil Girijavallabhan
Bama Santhanam
Patrick A Pinto
Hugh Y Zhu
Kartik M Keertikar
Carmen S Alvarez
John J Baldwin
Ge Li
Chia-Yu Huang
Ray A James
Robert W Bishop
James Wang
Jagdish A Desai
Original Assignee
Schering Corp
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Inc filed Critical Schering Corp
Publication of HK1054548A1 publication Critical patent/HK1054548A1/xx
Publication of HK1054548B publication Critical patent/HK1054548B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03105016.6A 2000-08-30 2003-07-11 法呢基蛋白轉移酶抑制劑三環抗腫瘤化合物 HK1054548B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918300P 2000-08-30 2000-08-30
PCT/US2001/026792 WO2002018368A1 (en) 2000-08-30 2001-08-28 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors

Publications (2)

Publication Number Publication Date
HK1054548A1 HK1054548A1 (en) 2003-12-05
HK1054548B true HK1054548B (zh) 2007-10-18

Family

ID=22860141

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105016.6A HK1054548B (zh) 2000-08-30 2003-07-11 法呢基蛋白轉移酶抑制劑三環抗腫瘤化合物

Country Status (27)

Country Link
US (1) US20020198216A1 (zh)
EP (1) EP1313725B1 (zh)
JP (1) JP2004513885A (zh)
KR (1) KR20030034161A (zh)
CN (1) CN100384837C (zh)
AR (1) AR033680A1 (zh)
AT (1) ATE359281T1 (zh)
AU (2) AU8845101A (zh)
BR (1) BR0113675A (zh)
CA (1) CA2420673A1 (zh)
CO (1) CO5640109A2 (zh)
DE (1) DE60127846T2 (zh)
EC (1) ECSP034494A (zh)
ES (1) ES2284686T3 (zh)
HK (1) HK1054548B (zh)
HU (1) HUP0302942A3 (zh)
IL (1) IL154528A0 (zh)
MX (1) MXPA03001849A (zh)
NO (1) NO20030918L (zh)
NZ (1) NZ524246A (zh)
PE (1) PE20020486A1 (zh)
PL (1) PL361103A1 (zh)
RU (1) RU2293734C9 (zh)
SK (1) SK2292003A3 (zh)
TW (1) TWI268280B (zh)
WO (1) WO2002018368A1 (zh)
ZA (1) ZA200301545B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
BRPI0207961B8 (pt) * 2001-03-14 2021-05-25 Bristol Myers Squibb Co uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
JP2005531488A (ja) * 2001-10-09 2005-10-20 ザ・ユニバーシティ・オブ・シンシナティ 甲状腺癌を処置するためのｅｇｆ受容体阻害剤
BR0214564A (pt) * 2001-11-30 2004-11-09 Schering Corp Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos
MXPA04005425A (es) * 2001-12-03 2004-10-11 Schering Corp Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer.
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
EP2260846B1 (en) * 2003-03-27 2018-11-28 Lankenau Institute for Medical Research Novel methods for the treatment of cancer
US20060281813A1 (en) * 2003-06-05 2006-12-14 Charles Rubin Methods of treating hyperproliferative cell disorders
WO2005001053A2 (en) * 2003-06-09 2005-01-06 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
KR20060057599A (ko) * 2003-08-07 2006-05-26 쉐링 코포레이션 항종양제로서 신규한 파르네실 단백질 트랜스퍼라제 억제제
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
US20060205755A1 (en) * 2004-12-21 2006-09-14 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
US8629135B2 (en) 2008-07-14 2014-01-14 Queen's University At Kingston Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer
EP3989956A1 (en) * 2019-06-28 2022-05-04 Anhui Ronghang Biotech Development Co., Ltd. Compositions and methods for treatment of hepatitis b virus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
HUP0203054A3 (en) * 1998-12-18 2004-01-28 Schering Corp Farnesyl protein transferase inhibitors, pharmaceutical compositions containing them and their use

Also Published As

Publication number Publication date
CN1471524A (zh) 2004-01-28
RU2293734C9 (ru) 2007-10-10
PE20020486A1 (es) 2002-06-14
SK2292003A3 (en) 2003-08-05
CO5640109A2 (es) 2006-05-31
ZA200301545B (en) 2004-06-22
NO20030918L (no) 2003-04-29
ATE359281T1 (de) 2007-05-15
MXPA03001849A (es) 2003-06-04
DE60127846T2 (de) 2008-03-06
RU2293734C2 (ru) 2007-02-20
AR033680A1 (es) 2004-01-07
TWI268280B (en) 2006-12-11
CN100384837C (zh) 2008-04-30
HK1054548A1 (en) 2003-12-05
EP1313725A1 (en) 2003-05-28
ECSP034494A (es) 2003-04-25
AU2001288451C1 (en) 2008-03-06
US20020198216A1 (en) 2002-12-26
WO2002018368A1 (en) 2002-03-07
AU2001288451B2 (en) 2007-05-24
AU8845101A (en) 2002-03-13
CA2420673A1 (en) 2002-03-07
NZ524246A (en) 2004-11-26
PL361103A1 (en) 2004-09-20
BR0113675A (pt) 2003-06-24
KR20030034161A (ko) 2003-05-01
HUP0302942A3 (en) 2007-02-28
HUP0302942A2 (hu) 2003-12-29
DE60127846D1 (en) 2007-05-24
EP1313725B1 (en) 2007-04-11
JP2004513885A (ja) 2004-05-13
NO20030918D0 (no) 2003-02-27
IL154528A0 (en) 2003-09-17
ES2284686T3 (es) 2007-11-16

Similar Documents

Publication Publication Date Title
AU2001240658A1 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
AU2001246477A1 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
IL173514A0 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
AU2001235496A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
AU2001234484A1 (en) Amide compounds for inhibiting protein kinases
IL154528A0 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
IL143409A0 (en) Farnesyl protein transferase inhibitors
AU2001239275A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001293835A1 (en) Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
AU2001252147A1 (en) Farnesyl protein transferase inhibitor combinations
AU2001247882A1 (en) Tricyclic protein kinase inhibitors
AU2001246478A1 (en) Farnesyl protein transferase inhibitor combinations with taxane compounds
IL163673A0 (en) Farnesyl protein transferase inhibitors as antitumor agents
AU2001253197A1 (en) Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
AU2001244167A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
IL143408A0 (en) Tricyclic farnesyl protein transferase inhibitors
DK1339695T3 (da) Farnesyltransferase-inhibitorer
AU2001242434A1 (en) Farnesyl protein transferase inhibitor combinations with vinca alkaloids
AU2435199A (en) Farnesyl transferase inhibitors
PL355887A1 (en) Farnesyl transferase inhibitors
AU3514302A (en) 0ovel farnesyl protein transferase inhibitors
IL149870A0 (en) Inhibitors of farnesyl protein transferase
AU2001251649A1 (en) Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase
IL141626A0 (en) Farnesyl transferase inhibitors

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: FROM SCHERING CORPORATION, PHARMACOPEIA, INC. ? TO PHARMACOPEIA DRUG DISCOVERY, INC., SCHERING CORPORATION ??

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110828